GSK to buy Aiolos Bio for $1.4 billion, boosting its respiratory portfolio
GSK completes acquisition of Aiolos Bio LONDON: GSK plc, a global pharmaceutical company, announced today that it has agreed to acquire Aiolos Bio, Inc., a clinical-stage biotech firm developing a novel antibody therapy for asthma and other inflammatory diseases, for…